An interventional study of Biopsy and Blood samples in Breast Cancer, sponsored by Institut Cancerologie de l'Ouest. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-31.
Sponsored by Institut Cancerologie de l'Ouest · Not applicable, Interventional, and Other
How we know · 3 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Breast Neoplasms by Institut Cancerologie de l'Ouest — 7 open to participants now, 12 under way, none of them phase 3. Breast Neoplasms · Institut Cancerologie de l'Ouest.
Among the 35 studies in Breast Neoplasms by Institut Cancerologie de l'Ouest, this one is the 6th largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2023, is one of 19 with no phase, reaches primary completion later than 8 of the 11 other live ones, and was the 29th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →7 of the 35 studies in Breast Neoplasms by Institut Cancerologie de l'Ouest are open now, in 1 country. Recruiting first, the newest first:
Institut Cancerologie de l'Ouest · Sites in France
Ages 18+
Institut Cancerologie de l'Ouest · Sites in France
Ages 18+ · Women only
Institut Cancerologie de l'Ouest · Sites in France
Ages 40+ · Women only
Institut Cancerologie de l'Ouest
Ages 18+ · Women only
Institut Cancerologie de l'Ouest · Sites in France
Ages 18+ · Women only
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 140 across the 23 interventional studies, 195 across the 12 observational. Of the 20 that completed or were terminated, 4 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
Institut Cancerologie de l'Ouest is the lead sponsor of 109 studies on the registry; 20 are open to participants now.
2 of the studies in Breast Neoplasms by Institut Cancerologie de l'Ouest that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06962163Institut Cancerologie de l'OuestAssessement of Potential Interest of [68Ga]Ga-PentixaFor PET/CT in Metastatic Triple Negative Breast Cancer Patients | 2027-06 |
| NCT06800989Institut Cancerologie de l'OuestTo Assess the Contribution of Sophrology Assisted by an Ambulatory Device on the Anxiety of Patients Undergoing Chemotherapy for the Treatment of Localized Breast Cancer | 2027-08-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 35 studies in Breast Neoplasms by Institut Cancerologie de l'Ouest, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Breast cancer (BC) is the most common cancer in women in France with nearly 58,500 new cases and 12,150 deaths estimated in 2018 .
Two major achievements have been made in the last five years for breast cancer patients. The first is therapeutic with the approval of immune checkpoint inhibitors in advanced and early triple-negative BC (TNBC) and the impressive efficacy of new antibody-drug conjugated in all BC subtypes. The second is conceptual with the generalization of adaptive therapeutic strategies guided by pathological responses after neoadjuvant therapy in early TNBC, HER2+, HR+ and BRCA mutated breast cancer. This new paradigm in the treatment of cancer patients completely redefined prognostic factors that were previously established with conventional approaches Pathological response remains a major prognostic factor especially for TNBC and HER2 early breast cancer. However, this parameter is evaluated at the end of neoadjuvant treatment and for patients with residual disease, the prognosis remains poor despite some adaptative strategies.
Our project is to integrate massive and heterogeneous data concerning the disease (clinical and biological data, imaging and histological results (with multi-omics data)) and patient's environment, personal and familial history. These data are multiple and have dynamic interactions overtime. With the help of mathematical units with biological competences and scientific collaborations, our project is to improve the prediction of treatment response, based on clinical and molecular heterogeneous big data investigation.
The main objective of this project is to set up a clinicobiological database prospectively by collecting prospective clinical, biological, pathological and multi-omic data from 300 Patients with early BC treated at the ICO in order to define an algorithm of individual decision for the prediction of the response to this treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Standard drug: Neoadjuvant treatment : Weekly paclitaxel + carboplatin + pembrolizumab (TCP) followed by EC90 \*4 pembrolizumab Procedure: supplementary biopsy at inclusion + centralized blood samples and questionnaires at evaluation visite
Procedure: Biopsy · Procedure: Blood samples · Behavioral: Questionnaires
Standard drug: EC100 followed by docetaxel + trastuzumab or EC100 followed by paclitaxel + trastuzumab Docetaxel + carboplatin + trastuzumab \*6 folowed by trastuzumab alone Procedure: supplementary biopsy at inclusion + centralized blood samples and questionnaires at evaluation visite
Procedure: Biopsy · Procedure: Blood samples · Behavioral: Questionnaires
Standard drug: EC100 paclitaxel or EC100 docetaxel Procedure: supplementary biopsy at inclusion + centralized blood samples and questionnaires at evaluation visite
Procedure: Biopsy · Procedure: Blood samples · Behavioral: Questionnaires
biopsy will be performed for multi-omicanalysis at inclusion before initiation of treatment
Centralized blood samples will be performed at inclusion + evaluation visits
Food inquiry + food-frequency questionnaire + physical activity questionnaire will be performed at inclusion
This study also gives PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., TrastuzumabStudies of TrastuzumabTrastuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
The accurancy predictive parameters for complete pathological response (pCR) after neoadjuvant chemotherapy
The primary endpoint is the predictive yield of complete pathological response (pCR) after the neoaduvant treatment
Time frame: 6 months after the initiation of neoadjuvant chemotherapy
To determine the rate of Event Free Survival
The primary endpoint is the predictive yield of Event Free Survial up to 5 years
Time frame: 5 years after the initiation of treatment
To determine the rate of Overall Survival
The primary endpoint is the predictive yield of overall Survival up to 5 years
Time frame: 5 years after the initiation of treatment
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2023 (actual). Primary completion is estimated for Apr 2028, 54 months after the start.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 54 months is above that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut Cancerologie de l'Ouest →